FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average I	ourden				
hours por rosponso	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* RABBANI SHAHRAM K				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]						_x_	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director 10% Owner				
(Last) (First) (Middle) C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE			3. Date of Earliest Transaction (Month/Day/Year) 09/23/2008					X	X Officer (give title below) Other (specify below) Treasurer and Secretary						
(Street) NEW YORK, NY 10022			4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu						Acquired,	lired, Disposed of, or Beneficially Owned				
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		if Code (Instr.	3. Transaction Code (A) (Instr. 8) (Instr. 8)		decurities Acquired or Disposed of (D) str. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)				7. Nature of Indirect Beneficial Ownership	
						Coo	le V	Amount	(A) or (D)	Price	or Indire (I)		. /	(Instr. 4)	
Common S share	Stock, par	value \$0.01 per	09/23/2008			М		60,755 (1)	A 5	5.45 1,82	8,494 ⁽²⁾			D	
Common S share	Stock, par	value \$0.01 per	09/23/2008			F		29,406 (1)	D 5	1,79	9,088 (2)			D	
						incerty of							on containe		1474 (9-02)
			Table II -		ve Secu	rities Acq	Perso in this a curr uired, Dis	form arently va	re not red lid OMB or Benefi	quired to re control nu icially Owne	espond u mber.		on containe form displa		1474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transact Code	ve Seculs, calls, 5. N of I Sec Acc or I of (rities Acq warrants Jumber Derivative urities uuired (A) Disposed D) tr. 3, 4,	Perso in this a curr	form arently va	re not red lid OMB or Benefi le securit	quired to re control nu icially Owne	espond u mber. ed		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	f 10. Owners Form o Derivat Securit Direct or India s) (I)	ship of India Benefic ive Owners (Instr. 4
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transact Code	ve Seculs, s, calls, 5. N ion of I Sec Acc or I of ((Ins	rities Acq warrants Jumber Derivative urities uuired (A) Disposed D) tr. 3, 4,	Perso in this a curr uired, Disp, options, of 6. Date Expiration	cosed of, convertib corcisable a Date ay/Year)	re not reclid OMB or Benefi le securit and	control nucleically Owneries) 7. Title and of Underly Securities	espond u mber. ed	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	f 10. Owners Form o Derivat Securit Direct or India	ship of India Benefic ive Owners (Instr. 4

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
RABBANI SHAHRAM K C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK, NY 10022	X		Treasurer and Secretary			

Signatures

/s/ Shahram Rabbani	09/25/2008
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person exercised a stock option to purchase 60,755 shares of Common Stock and paid the exercise price thereof by the surrender of 29,406 shares of Common Stock, for a net gain in outstanding shares of Common Stock of 31,349 shares. The stated exercise price of the stock option was \$5.45.
- Includes (i) 398,773 shares of Common Stock issuable upon the exercise of options which are exercisable within 60 days from the date hereof, (ii) 1,354 shares of Common Stock held in the (2) name of the Reporting Person's son, (iii) 1,671 shares of Common Stock that the Reporting Person holds as custodian for certain of his nephews, (iv) 3,500 shares of restricted Common Stock, and (v) 4,881 shares of Common Stock held in the Company's 401(k) plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.